Transdermal compositions for anticholinergic agents
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-031/216
A61K-047/00
A61K-009/06
A61K-031/56
A61K-047/10
A61K-047/32
A61K-047/38
출원번호
US-0614216
(2009-11-06)
등록번호
US-8980290
(2015-03-17)
우선권정보
WO-PCT/EP00/07533 (2000-08-03)
발명자
/ 주소
Carrara, Dario Norberto R.
Grenier, Arnaud
출원인 / 주소
Antares Pharma IPL AG
대리인 / 주소
Winston & Strawn LLP
인용정보
피인용 횟수 :
0인용 특허 :
139
초록▼
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation whic
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
대표청구항▼
1. A composition for transdermal or transmucosal administration of oxybutynin consisting essentially of: oxybutynin in an amount between 1 to 3% by weight of the composition;a delivery vehicle which consists essentially of a C2 to C4 alkanol present in an amount of 45 to no more than 65% by weight o
1. A composition for transdermal or transmucosal administration of oxybutynin consisting essentially of: oxybutynin in an amount between 1 to 3% by weight of the composition;a delivery vehicle which consists essentially of a C2 to C4 alkanol present in an amount of 45 to no more than 65% by weight of the composition, a polyalcohol selected from the group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof in an amount greater than 15 to about 30% by weight of the composition, a monoalkyl ether of diethylene glycol in an amount between about 1 to 5% by weight of the composition, and water, so that the delivery vehicle provides permeation enhancement of oxybutynin through mammalian dermal or mucosal surfaces; andoptionally at least one excipient selected from the group consisting of gelling agents, antimicrobials, preservatives, and neutralizing agents. 2. The composition of claim 1, wherein the oxybutynin is present as oxybutynin free base, as a pharmaceutically acceptable salt of oxybutynin, or as a mixture thereof. 3. The composition of claim 2, wherein the pharmaceutically acceptable salt of oxybutynin is selected from the group consisting of acetate, bitartrate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hydrobromide, hydrochloride, lactate, malate, maleate, mandelate, mesylate, methylnitrate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, salicylate, stearate, succinate, sulfate, tannate and tartrate. 4. The composition of claim 1, wherein the alkanol is selected from the group consisting of ethanol, isopropanol, n-propanol, and mixtures thereof; wherein the polyalcohol is selected from the group consisting of propylene glycol, dipropylene glycol, and mixtures thereof; and wherein the monoalkyl ether of diethylene glycol is selected from the group consisting of monomethyl ether of diethylene glycol, monoethyl ether of diethylene glycol, and mixtures thereof. 5. The composition of claim 1, wherein the at least one excipient selected from the group consisting of gelling agents, antimicrobials, preservatives, and neutralizing agents is present. 6. The composition of claim 1 wherein the formulation is in the form of a topical gel, lotion, foam, cream, spray, aerosol, ointment, emulsion, microemulsion, nanoemulsion, suspension, liposomal system, lacquer, patch, bandage, or occlusive dressing. 7. The composition according to claim 1 wherein the polyalcohol is present in an amount between about 20 to 30% by weight of the composition. 8. The composition according claim 1, wherein the oxybutynin is present as oxybutynin free base; and wherein the alkanol is selected from a group consisting of ethanol, isopropanol, and a mixture thereof in an amount between about 45 and 60% by weight of the composition; the polyalcohol is propylene glycol; the monoalkyl ether of diethylene glycol is monoethyl ether of diethylene glycol; and the polyalcohol and monoethyl ether of diethylene glycol are present in a weight ratio of 8:1. 9. A method for administering oxybutynin to a mammal in need thereof which comprises topically or transdermally administering to the skin or the mucosa of a mammal a composition according to claim 1. 10. The method of claim 9, wherein the mammal is a human and the oxybutynin is administered for treating hyperactivity of the detrusor muscle with frequent urge to urinate, increased urination during the night, urgent urination, involuntary urination with or without the urge to urinate, painful or difficult urination, detrusor hyperreflexia and detrusor instability. 11. The method of claim 10, wherein a daily dose of oxybutynin of between about 40 and about 100 mg is administered upon the abdomen, shoulder, arm, or thigh of the subject. 12. A composition for transdermal or transmucosal administration of oxybutynin consisting of: oxybutynin present as oxybutynin free base, as a pharmaceutically acceptable salt of oxybutynin, or as a mixture thereof and in an amount between 1 to 3% by weight of the composition;a delivery vehicle which consists of a C2 to C4 alkanol present in an amount of between about 45 to no more than 65% by weight of the composition, a polyalcohol selected from a group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof in an amount above 15 to 30% by weight of the composition, a monoalkyl ether of diethylene glycol in an amount between about 1 to 5% by weight of the composition, and water, to provide permeation enhancement of oxybutynin through mammalian dermal or mucosal surfaces; andoptionally at least one excipient selected from the group consisting of gelling agents, preservatives, and neutralizing agents. 13. The composition of claim 12, wherein the pharmaceutically acceptable salt of oxybutynin is selected from the group consisting of acetate, bitartrate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hydrobromide, hydrochloride, lactate, malate, maleate, mandelate, mesylate, methylnitrate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, salicylate, stearate, succinate, sulfate, tannate and tartrate. 14. The composition of claim 12, wherein the alkanol is selected from the group consisting of ethanol, isopropanol, n-propanol, and mixtures thereof; the polyalcohol is selected from the group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof and the monoalkyl ether of diethylene glycol is selected from the group consisting of monomethyl ether of diethylene glycol, monoethyl ether of diethylene glycol, and mixtures thereof. 15. The composition of claim 12, wherein the formulation is in the form of a topical gel. 16. The composition of claim 12, wherein the alkanol is present in an amount between about 45 and 60% by weight of the composition; the polyalcohol is present in an amount between about 20 to 30% by weight of the composition; the monoalkyl ether of diethylene glycol is monoethyl ether of diethylene glycol; and the polyalcohol and monoethyl ether of diethylene glycol are present in a weight ratio of 8:1. 17. A composition for transdermal or transmucosal administration of oxybutynin consisting of: oxybutynin present as oxybutynin free base, as a pharmaceutically acceptable salt of oxybutynin, or as a mixture thereof and in an amount between 1 to 3% by weight of the composition;a delivery vehicle which consists of ethanol present in an amount of between about 45 to no more than 60% by weight of the composition, a polyalcohol selected from a group consisting of propylene glycol and dipropylene glycol in an amount above 15 to about 20% by weight of the composition, monoethyl ether of diethylene glycol in an amount between about 1 to 5% by weight of the composition, and water, to provide permeation enhancement of oxybutynin through mammalian dermal or mucosal surfaces, with the polyalcohol and monoethyl ether of diethylene glycol present in a weight ratio of 8:1;an excipient of a gelling agent so that the composition is in the form of a gel; and optionally at least one excipient selected from the group consisting of preservatives, and neutralizing agents. 18. The composition of claim 17, wherein the oxybutynin is present as oxybutynin free base in an amount of 3% by weight of the composition, the polyalcohol is propylene glycol in an amount of about 20% by weight of the composition, and the monoethyl ether of diethylene glycol is present in an amount of about 2.5% by weight of the composition. 19. The composition of claim 18, wherein gelling agent is present in an amount of 0.3% to 2%, and the neutralizing agent is hydrochloric acid. 20. The composition of claim 19, wherein the oxybutynin is present as the free base and in an amount of 3% by weight of the composition; and, the ethanol is anhydrous ethanol present in an amount of about 50.72% by weight of the composition, the polyalcohol is propylene glycol present in an amount of about 20% by weight of the composition, the monoethyl ether of diethylene glycol is present in an amount of about 2.5% by weight of the composition, the gelling agent is hydroxypropylcellulose in an amount of about 1 to 2% by weight of the composition, and the preservative is butylhydroxytoluene in an amount of about 0.05% by weight of the composition.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (139)
Piasco Alain,FRX ; Lafay Jean,FRX ; Delansorne Remi,FRX ; Paris Jacques,FRX ; Pascal Jean-Claude,FRX, 19-nor-pregnene derivatives and pharmaceuticals containing such derivatives.
David Scott Dunlop ; Susan Marie Guskey ; Vicente Eduardo Leyba VE; Douglas Allan Royce, Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers.
Hartell, Mark G.; Bhattacharjee, Apurba K.; Hicks, Rickey P.; VanHamont, John E.; Milhous, Wilbur K., Artemisinins with improved stability and bioavailability for therapeutic drug development and application.
Carrara,Dario; Porto,Gabriel; Rodriguez,Jorge, Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Stella Valentino J. (Lawrence KS) Rajewski Roger (Lawrence KS), Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Iles Martin C. (7 Cartwright Drive Shaw ; Swindon ; Wiltshire GBX) Atherton Angela D. (170 ; Windsor Drive Chelsfield ; Orpington ; Kent GBX) Copping Neil M. (8 Lautrec Way Haydon Hill ; Aylesbury ; , Freeze-dried dosage forms and methods for preparing the same.
Al-Razzak Laman A. ; Constantinides Panayiotis Pericleous ; Kaul Dilip ; Lipari John M. ; McChesney-Harris Lisa L. ; Abdullah Bashar Y., Hydrophilic binary systems for the administration of lipophilic compounds.
Wong Ooi (Fremont CA) Farinas Kathleen C. (San Francisco CA) Cleary Gary W. (Menlo Park CA) Chiang Chia-Ming (Foster City CA) Xia Jun (Redwood City CA), Method and device for providing nicotine replacement therapy transdermally/transbuccally.
Campbell Patricia S. (Palo Alto CA) Enscore David J. (Sunnyvale CA) Gale Robert M. (Los Altos CA) Kaufman Arnold (Palo Alto CA), Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix.
Osborne James L. (2365 Thompson Ct. Mountain View CA 94043) Nelson Melinda K. (1127 Hollenbeck Sunnyvale CA 94087) Enscore David J. (18291 Montpere Way Saratoga CA 95070) Yum Su I. (1021 Runnymead Ct, Method of administering nicotine transdermally.
Young James W. ; Brandt Steven, Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+).
Aberg Gunnar (Westborough MA) McCullough John R. (Worcester MA), Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin.
Berner Bret (Scarsdale NY) Ebert Charles (Salt Lake City UT) Mazzenga Gerard C. (New City NY) Otte John H. (Monsey NY), Mixed solvent mutually enhanced transdermal therapeutic system.
Kasting Gerald B. (Wyoming OH) Massaro Ellen R. (Cincinnati OH) Smith Ronald L. (West Chester OH) Snyder William E. (Cincinnati OH), Penetrating topical pharmaceutical compositions.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Rhodes John,GBX ; Rhodes Peter,GBX ; Evans Brian Kenneth,GBX, Pharmaceutical products containing a complex of an amide-type local anesthetic and a polyacrylate.
Punto Louis L. (Northport NY) Zecchino Jules R. (Closter NJ) Lentini Peter J. (Glen Oaks NY), Self-tanning cosmetic compositions and methods of using the same.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Stttgen Gnter (Berlin DEX) Schaefer Hans (Berlin DEX), Topical combinations of an a
상세보기
Sato ; deceased Toshiya (late of Kanagawa JPX by Kuniko Sato ; legal representative) Ishida Kenya (Kanagawa JPX), Topical composition for treating acne vulgaris.
Lipp Ralph,DEX ; Gunther Clemens,DEX ; Riedl Jutta,DEX ; Tauber Ulrich,DEX, Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.